Top

Published in:

01-03-2013 | IM - REVIEW

Recent advances in understanding Crohn’s disease

Authors: Antonio Di Sabatino, Laura Rovedatti, Francesca Vidali, Thomas Thornton MacDonald, Gino Roberto Corazza

Published in: Internal and Emergency Medicine | Issue 2/2013

Abstract

Crohn’s disease is a chronic inflammatory bowel disorder resulting from an inappropriate innate and acquired immune response to commensal microorganisms in genetically susceptible individuals. This disease has a fluctuating course, with alternating periods of remission and relapses, and it is characterized by a remarkable clinical heterogeneity; it may be complicated by perianal fistulas, abscesses, and intestinal strictures leading to obstructions, besides several systemic manifestations. However, a complete resolution of the disease is currently not possible, yet Crohn’s disease can be managed with established and novel therapies, which achieve long-term remission and acceptable quality of life. This review is focused on novel advances in basic and clinical aspects of Crohn’s disease, although it also deals with new trends in diagnosis and treatment.

Hou JK, El-Serag H, Thirumurthi S (2009) Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 104:2100–2109PubMedCrossRef

Zlotogora J, Zimmerman J, Rachmilewitz D (1990) Crohn’s disease in Ashkenazi Jews. Gastroenterology 99:286–287PubMed

Bernstein CN, Shanahan F (2008) Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 57:1185–1191PubMedCrossRef

Loftus EV Jr (2004) Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126:1504–1517PubMedCrossRef

Halme L, Paavola-Sakki P, Turunen U et al (2006) Family and twin studies in inflammatory bowel disease. World J Gastroenterol 12:3668–3672PubMed

Franke A, McGovern DP, Barrett JC et al (2010) Genome-wide meta-analysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci. Nat Genet 42:1118–1125PubMedCrossRef

Ogura Y, Bonen DK, Inohara N et al (2001) A frameshift mutation inNOD2 associated with susceptibility to Crohn’s disease. Nature 411:603–606PubMedCrossRef

Strober W, Kitani A, Fuss I (2008) The molecular basis of NOD2 susceptibility mutations in Crohn’s disease. Mucosal Immunol 1((Supp 1)):S5–S9PubMedCrossRef

Noomen CG, Hommes DW, Fidder HH (2009) Update on genetics in inflammatory disease. Best Pract Res ClinGastroenterol 23:233–243CrossRef

10.

Fiocchi C (2009) Susceptibility genes and overall pathogenesis of inflammatory bowel disease: where do we stand? Dig Dis 27:226–235PubMedCrossRef

11.

Kaser A, Zeissig S, Blumberg RS (2010) Inflammatory bowel disease. Annu Rev Immunol 28:573–621PubMedCrossRef

12.

Ma TY, Iwamoto GK, Hoa NT et al (2004) TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J PhysiolGastrointest Liver Physiol 286:G367–G376CrossRef

13.

Rescigno M, Di Sabatino A (2009) Dendritic cells in intestinal homeostasis and disease. J Clin Invest 119:2441–2450PubMedCrossRef

14.

MacDonald TT, Monteleone G (2005) Immunity, inflammation, and allergy in the gut. Science 307:1920–1925PubMedCrossRef

15.

Abraham C, Cho J (2009) Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 15:1090–1100PubMedCrossRef

16.

Laan M, Lötvall J, Chung KF et al (2001) IL-17-induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases. Br J Pharmacol 133:200–206PubMedCrossRef

17.

Rovedatti L, Kudo T, Biancheri P et al (2009) Differential regulation of interleukin-17 and interferon-γ production in inflammatory bowel disease. Gut 58:1629–1636

18.

Rieder F, Fiocchi C (2009) Intestinal fibrosis in IBD—a dynamic, multifactorial process. Nat Rev 6:228–235

19.

Di Sabatino A, Jackson CL, Pickard KM et al (2009) Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease structures. Gut 58:777–789

20.

van der Heide F, Dijkstra A, Weersma RK et al (2009) Effects of active and passive smoking on disease course of Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 15:1199–1207PubMedCrossRef

21.

Feller M, Huwiler K, Stephan R et al (2007) Mycobacterium avium subspecies paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infect Dis 7:607–613PubMedCrossRef

22.

Selby W, Pavli P, Crotty B et al (2007) Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology 132:2313–2319PubMedCrossRef

23.

Singh S, Graff LA, Bernstein CN (2009) Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 104:1298–1313PubMedCrossRef

24.

Cornish JA, Tan E, Simillis C et al (2008) The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 103:2394–2400PubMedCrossRef

25.

Collins SM, Bercik P (2009) The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136:2003–2014PubMedCrossRef

26.

Lakatos PL (2009) Environmental factors affecting inflammatory bowel disease: have we made progress? Dig Dis 27:215–225PubMedCrossRef

27.

Gasche C, Scholmerich J, Brynskov J et al (2000) A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6:8–15PubMedCrossRef

28.

Cosnes J, Cattan S, Blain A et al (2002) Long-term evolution of disease behaviour of Crohn’s disease. Inflamm Bowel Dis 8:244–250PubMedCrossRef

29.

Canavan C, Abrams KR, Mayberry J (2006) Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther 23:1097–1104PubMedCrossRef

30.

Best WR, Becktel JM, Singleton JW et al (1976) Development of a Crohn’s disease activity index National Cooperative Crohn’s Disease Study. Gastroenterology 70:439–444PubMed

31.

Fraquelli M, Sarno A, Girelli C et al (2008) Reproducibility of bowel ultrasonography in the evaluation of Crohn’s disease. Dig Liver Dis 40:860–866PubMedCrossRef

32.

Saibeni S, Rondonotti E, Iozzelli A et al (2007) Imaging of the small bowel in Crohn’s disease: a review of old and new techniques. World J Gastroenterol 13:3279–3287PubMed

33.

Gourtsoyiannis NC, Grammatikakis J, Papamastorakis G et al (2006) Imaging of small intestinal Crohn’s disease: comparison between MR enteroclysis and conventional enteroclysis. EurRadiol 16:1915–1925

34.

Löffler M, Weckesser M, Franzius C et al (2006) High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci USA 1072:379–385CrossRef

35.

Sandborn WJ, Feagan BG, Lichtenstein GR (2007) Medical management of mild to moderate Crohn’s disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 26:987–1003PubMedCrossRef

36.

Peyrin-Biroulet L, Deltenre P, de Suray N et al (2008) Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6:644–653PubMedCrossRef

37.

Hanauer SB, Wagner CL, Bala M et al (2004) Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2:542–553PubMedCrossRef

38.

Vermeire S, Noman M, Van Assche G et al (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 56:1226–1231PubMedCrossRef

39.

Farrell RJ, Alsahli M, Jeen YT et al (2003) Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 124:917–924PubMedCrossRef

40.

Hanauer SB, Sandborn WJ, Rutgeerts P et al (2006) Human anti-tumour necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333PubMedCrossRef

41.

Sandborn WJ, Feagan BG, Stoinov S et al (2007) Certolizumabpegol for the treatment of Crohn’s disease. N Engl J Med 357:228–238PubMedCrossRef

42.

Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF (2008) Crohn’s disease: beyond antagonists of tumour necrosis factor. Lancet 372:67–81PubMedCrossRef

43.

MacDonald TT (2010) Inside the microbial and immune labyrinth. Nat Med 16:1194–1195PubMedCrossRef

44.

MacDonald JK, McDonald JW (2007) Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev(1):CD006097

45.

Dignass A, van Assche G, Lindsay JO, European Crohn’s, Colitis Organisation (ECCO) et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 4:28–62PubMedCrossRef

46.

Yamamoto T, Umegae S, Matsumoto K (2009) Impact of infliximab therapy after early endoscopic recurrence following ileocolonic resection of Crohn’s disease: a prospective pilot study. Inflamm Bowel Dis 15:1460–1466PubMedCrossRef

Title: Recent advances in understanding Crohn’s disease
Authors: Antonio Di Sabatino
Laura Rovedatti
Francesca Vidali
Thomas Thornton MacDonald
Gino Roberto Corazza
Publication date: 01-03-2013
Publisher: Springer Milan
Published in: Internal and Emergency Medicine / Issue 2/2013
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-011-0599-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Challenges in dealing with a cirrhotic patient

Verification of correct central venous catheter placement in the emergency department: comparison between ultrasonography and chest radiography

Ischaemic stroke and thrombolysis: ask the onset time, not the age!

Inflammatory activation in an unselected population of subjects with atrial fibrillation: links with structural heart disease, atrial remodeling and recent onset

Acute mitral regurgitation due to flail mitral leaflet mimicking: a diagnosis of pneumonia

Early invasive strategy and outcomes of non-ST-elevation acute coronary syndrome patients: is time really the major determinant?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials